ACT Stock News 205.55 05/15/2014 17:52:06 Actavis Inc (ACT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actavis Inc (ACT) 205.55 $ACT

Actavis signs agreement to extend distribution of JPI's Concerta
M2 - Thu May 15, 10:14AM CDT
Pharmaceutical company Actavis plc (NYSE:ACT) announced on Thursday that it has extended an agreement with Janssen Pharmaceuticals Inc (JPI) to supply the authorised generic version of JPI's Concerta (methylphenidate hydrochloride extended-release tablets).

Actavis Extends Exclusive Agreement to Distribute Authorized Generic Concerta®
PR Newswire - Thu May 15, 7:45AM CDT
Actavis plc (NYSE: ACT) today announced that it has reached an agreement with Janssen Pharmaceuticals, Inc. (JPI) to continue supplying the authorized generic version of JPI's Concerta® (methylphenidate hydrochloride extended-release tablets).

Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Forest Laboratories Acquisition
PR Newswire - Wed May 14, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year. Following the close, Paul Bisaro, Chairman and Chief Executive Officer of Actavis, will become Executive Chairman. Brent Saunders, currently CEO and President of Forest, will become CEO and President, and a member of the Board of Directors. Robert Stewart, President, Actavis Global Operations, will become Chief Operating Officer. Mr. Saunders will report to Mr. Bisaro and the Board of Directors, and Mr. Stewart will report to Mr. Saunders.

Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie
PR Newswire - Wed May 14, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Bristol-Myers Squibb Company (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2434-100free.

Actavis Receives Final Approval for Generic Version of Exalgo®
PR Newswire - Tue May 13, 4:00PM CDT
Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo® (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity.

Actavis to Present at Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014
PR Newswire - Tue May 13, 3:45PM CDT
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 in New York City.

Actavis Announces Acanya® Gel Patent Challenge Settlement
PR Newswire - Mon May 12, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya® (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%. Acanya® Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris.

Technical Coverage on Pharma Equities -- Research on Allergan, Actavis, Medicines Co., and Akorn
PR Newswire - Fri May 09, 10:30AM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,550.97, and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished positive. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, and the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Actavis PLC (NYSE: ACT), The Medicines Company (NASDAQ: MDCO) and Akorn Inc. (NASDAQ: AKRX). Free technical research on AGN, ACT, MDCO and AKRX can be downloaded upon signing up at:

Actavis Launches Generic Version of Catapres-TTS®
PR Newswire - Wed May 07, 3:05PM CDT
Actavis plc (NYSE: ACT) today announced that it has launched a generic version of Boehringer Ingelheim's Catapres-TTS® (Clonidine Transdermal System, USP, 0.1 mg/day, 0.2 mg/day, and 0.3 mg/day for one week), following the receipt of final approval on its Abbreviated New Drug Application from the U.S. Food and Drug Administration.

Acorda Misses on Earnings, Beats Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:43PM CDT
Acorda Therapeutics, Inc.'s (ACOR) first quarter earnings of 2 cents per share missed the Zacks Consensus Estimate of 4 cents.

What Does Celgene's May 15 Markman Hearing Mean to You?
at The Street - Wed May 07, 9:11AM CDT
Celgene faces a big hearing over patents on its franchise product. Here's what investors need to know.

Actavis, Michael Kors Among World Stocks Near Buy Points
at Investor's Business Daily - Tue May 06, 5:50PM CDT
Leading international stocks have proved highly resilient amid the market's correction. Two of IBD's current Top World Stocks, Ireland's Shire (SHPG) and Singapore-based Avago Technologies (AVGO), recently cleared buy points and moved to new highs....

Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
PR Newswire - Tue May 06, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2075-100free.

Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4
Business Wire - Mon May 05, 8:01AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC" by Actavis plc on March 25, 2014 and amended on May 2, 2014 (the "Form S-4" , which includes a joint proxy statement of Actavis and Forest, was declared effective on May 2, 2014. The Form S-4 is available on the SEC's EDGAR system, and may be accessed at https://www.sec.gov/Archives/edgar/data/15788...59ds4a.htm.

AstraZeneca Nixes New Bid As Pfizer Woos British PM
at Investor's Business Daily - Fri May 02, 1:11PM CDT
British big pharma AstraZeneca (AZN) turned down a second takeover bid from U.S. counterpart Pfizer (PFE) Friday, saying that the $106 billion offer was still too low. Pfizer's stock dropped nearly 2%, while AstraZeneca's held steady on the stock...

Earnings Beat at Endo, Shares Up on Improved Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 11:10AM CDT
Endo (ENDP) beat on earnings in the first quarter.

A Look At World Stocks' Q1: Shire, Actavis, NXP Semi
at Investor's Business Daily - Thu May 01, 4:32PM CDT
Only a few IBD Top World Stocks have so far reported Q1 results. But the trend through Thursday has been very positive. Dublin, Ireland-based Shire (SHPG) retook a 172.37 buy point Thursday after reporting mixed first-quarter results. Earnings swung...

What's With All The Healthcare And Pharmaceutical Mergers?
at The Street - Thu May 01, 4:25PM CDT
James Dennin, Kapitall: Last Tuesday alone saw the announcement of $74 billion in potential healthcare and pharmaceutical mergers. In one day. [...]

Avanir Wins Lawsuit, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:39PM CDT
Shares of Avanir (AVNR) soared 45.6% after the the U.S. District Court for the District of Delaware has ruled the patent infringement lawsuit in its favor.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 86

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 72

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 7

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading
Vail’s Board Fight Puts Strategy Under a Sharp Lens

Updated Category News Views 123

Fresh snow does not make a boardroom dispute disappear. Vail Resorts has put out an investor presentation ahead of its December 14, 2026 annual meeting, asking shareholders to support all nine of management’s director nominees on its white proxy card. That is the formal message. The real message is plainer: NYSE:MTN knows this election has become a test of whether...

Continue Reading
The Estate Bets Over $1 Billion on Luxury Longevity

Updated Category News Views 108

A billion-dollar wellness promise just wandered into the condominium market. The Estate by sbe says its first three branded residential developments carry combined real estate value above $1 billion and encompass more than 500 units. That is not pocket change, and it is certainly not a routine hotel-brand licensing exercise dressed up with scented candles and a cold...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 99

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 143

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
DSFederal Takes On USDA NIFA Grants System Support Work

Updated Category News Views 0

A Quiet Contract With Real Operational Weight Grant paperwork rarely gets anybody’s pulse racing, yet a busted grants system can gum up research money from coast to coast in a hurry. DSFederal has won work supporting the U.S. Department of Agriculture’s National Institute of Food and Agriculture, or NIFA, through its Grants Management and Reporting System, known as...

Continue Reading
SwitchBot's Black Friday Sale Tests Smart Home Demand

Updated Category News Views 112

Holiday gadget season is where clever home-tech pitches either earn their keep or gather dust in a warehouse. SwitchBot is coming into Black Friday 2026 with discounts of up to 50% on select products, running from November 19 through Cyber Monday on November 30. The lineup is broad enough to matter: decorative color E Ink frames, automated curtains and blinds, an indoor...

Continue Reading
Nike Locks In Chicago Marathon Partnership Through 2036 Deal

Updated Category News Views 13

Twenty-eight miles of pavement, training plans, and branded shoes are not a quarterly earnings release, but Nike just made a very long-term statement in Chicago. The company and the Bank of America Chicago Marathon have extended their partnership through 2036, preserving a relationship that began in 2008. For a brand rebuilding credibility with runners, that kind of...

Continue Reading

Top 5 Most Recently Viewed Articles

Navigating Component Obsolescence: Key Trends and Insights

Updated Category News Views 170

Understanding Component Obsolescence in Today's Market In the rapidly evolving world of semiconductors and electronic components, tracking obsolescence has become crucial. Bill Bradford, President of Flip Electronics, sheds light on these trends that are shaping the industry as we move towards 2026. The market has seen a significant shift, primarily due to increasing...

Continue Reading
Exploring Class Action Claims Against iLearningEngines - AILE

Updated Category News Views 181

Understanding the Class Action Lawsuit Against iLearningEngines Faruqi & Faruqi, LLP, a prominent name in securities litigation, is taking steps to inform investors about a significant class action lawsuit related to iLearningEngines, Inc. The law firm, known for its commitment to protecting investors' rights, has set a deadline for potential lead plaintiffs in this case....

Continue Reading
Key Stock Movements: Sanmina and other Performers Soar

Updated Category News Views 440

Key Stock Movements on Tuesday U.S. stocks exhibited mixed performance with the Dow Jones index declining around 100 points. Despite the overall market volatility, several companies reported substantial improvements in their stock values on Tuesday. Sanmina Corporation Performance Sanmina Corporation (NASDAQ: SANM) saw an impressive rise in its stock during Tuesday's...

Continue Reading
Segal Trials' Innovations in Schizophrenia Treatment with LB-102

Updated Category News Views 303

Segal Trials Advances Schizophrenia Research with LB-102 Segal Trials is making significant strides in the field of schizophrenia research, focusing on the innovative treatment method involving LB-102. This investigational drug, which is a potential first-in-class benzamide antipsychotic, is being evaluated in a Phase 2 trial. The main goal of this study is to assess the...

Continue Reading
Innovative Vehicle Safety System Promises Improved Driver Focus

Updated Category News Views 237

Introduction to an Innovative Safety Solution In today's fast-paced world, driving distractions can have serious consequences. An inventive mind has created a new device called SAFE DRIVE, aimed at enhancing driver concentration and reducing the risks associated with smartphone usage while driving. Concept Behind SAFE DRIVE The SAFE DRIVE invention is designed with a...

Continue Reading